Background We recently reported a favorable effect of celecoxib for 6 month in reducing neointima formation without risk in thrombotic events after angioplasty with TAXUS stent (COREA-TAXUS trial). The aim of this study was to evaluate the anti-restenotic effect of celecoxib for 3 month after angioplasty with TAXUS stent. Methods From 2006.3 to 2007.6, we enrolled 230 patients in a randomized, two-center trial to compare the effects of 3 month administration of celecoxib with conventional therapy after coronary intervention using paclitaxel-eluting stents. Among 230 patients, 146 and 133 patients finished 6 month clinical and angiographic follow-up. The primary endpoint was late luminal loss on quantitative coronary angiography. Secondary end points were major adverse cardiac events (MACE) including cardiac death, non-fatal myocardial infarction, and target lesion revascularization. Results The baseline lesion characteristics were comparable and equally complex in both groups. The mean diameter of the stent was 3.1짹0.4 mm for celecoxib group and 3.0짹0.3 mm for control group. The mean length of the stent was 28.5짹14.2 mm for celecoxib group and 27.4짹11.4 mm for control group. At 6 months, in-stent late luminal loss was lower in the celecoxib group (n=30) compared with the control group (n=50) although this difference failed to reach the statistical significance with small sample size (0.54 vs 0.35 mm, delta=0.19 mm, p=0.09). MACE at 6 months was also lower in the celecoxib group although this difference failed to reach the statistical significance (3 [4.3%] vs 10 [13%], p=0.08).